ResearcherUniversity of California, San FranciscoNo recent work listed
Olga K. Mirzoeva
Matched on ORCID iD 0000-0002-5564-1564; OpenAlex author ID A5042234427. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper
Papers 3
- A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-15-0979↗
- Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Co-author DOI 10.1158/1535-7163.mct-13-0104↗
- Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. Co-author DOI 10.1007/s00109-011-0774-y↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wolfgang Michael Korn · 3 shared papers, 2011–2016 · strength 0.12
- Paper A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Adva… DOI 10.1158/1078-0432.ccr-15-0979↗
- Paper Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. DOI 10.1158/1535-7163.mct-13-0104↗
- Paper Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic ad… DOI 10.1007/s00109-011-0774-y↗
- Andrew H. Ko · 2 shared papers, 2013–2016 · strength 0.09
- Eric Andrew Collisson · 2 shared papers, 2013–2016 · strength 0.09
- Peter Kühn · 1 shared paper, 2016 · strength 0.05
- Alan Paul Venook · 1 shared paper, 2016 · strength 0.05
- Tanios Bekaii‐Saab · 1 shared paper, 2016 · strength 0.05
- Margaret A. Tempero · 1 shared paper, 2016 · strength 0.05
- Kevan M Shokat · 1 shared paper, 2011 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.